Sir,
We read with interest the paper on clinical outcomes in patients with COVID-19 and pre-existing type 2 diabetes [1]. In the COVID-19 pandemics, several patients are affected by co-morbidities such as cardiovascular diseases (CVD), diabetes, and obesity. The pathogenic mechanism is far from being understood, but recent evidence shows that the severity of SARS-CoV-2 infection is attributable, rather than to the virus itself, to pro-inflammatory cytokine storm and to exaggerated systemic inflammation, that trigger abnormal activation of coagulative cascade and thrombotic states [2]. A meta-analysis shows that patients with diabetes [DM] have an incidence of Covid-19 similar to patients without DM [3], but DM patients show a worse prognosis [1], [4], [5], mainly depending on hyperglycemia. If it were only a matter of metabolic control, the COVID-19 disease would not be different from previous viral SARS epidemics, in which diabetes was a risk factor for bad prognosis [6]. However, in these studies [1], [4], [5], body mass index (BMI) is not considered; when investigated, obesity was more prevalent than diabetes [7], and increasing evidence shows that obesity is itself a bad prognostic factor as to admission to intensive care units, invasive ventilation, and death [8], [9]. Obesity shares pro-thrombotic and pro-inflammatory patterns with DM [8], [9], and has profound mechanical effects on respiration [10]. Therefore, we speculate that BMI and BG play an additional or synergistic role in the bad prognosis of COVID-19 in DM. Intensifying the treatment of obese patients, who are also diabetic, might be important in yielding a better prognosis.
Ethical statement
Does not apply.
Funding
This paper was supported by Università degli Studi di Milano, by IRCCS Multimedica, and by Ministero della Salute, Italy.
Authors contributions
AEP, LSL, DC, and FF participated equally in study design; antonio e pontiroli and lucia la sala performed literature search; all authors performed interpretation of data, and all authors contributed to writing the manuscript.
Declaration of Competing Interest
AEP, LSL, DC, and FF have no conflict of interest with the contents of this paper.
References
- 1.Alkundi A., Mahmoud I., Musa A., Naveed S., Alshawwaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study [published online ahead of print, 2020 Jun 10] Diabetes Res Clin Pract. 2020;165:108263. doi: 10.1016/j.diabres.2020.108263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Dolhnikoff M., Duarte-Neto A.N., de Almeida Monteiro R.A., Ferraz da Silva L.F., Pierre de Oliveira E. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020 doi: 10.1111/jth.14844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mantovani A., Byrne C.D., Zheng M.H., Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020 doi: 10.1016/j.numecd.2020.05.014. S0939-4753(20)30207-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Guo W., Li M., Dong Y., Zhou H., Zhang Z., Tian C. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319. doi: 10.1002/dmrr.3319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809. doi: 10.1001/jama.289.21.JOC30885. [DOI] [PubMed] [Google Scholar]
- 7.Richardson S., Hirsch J.S., Narasimhan M. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Simonnet A., Chetboun M., Poissy J., Raverdy V., Noulette J., Duhamel A., Labreuche J., Mathieu D., Pattou F., Jourdain M., Caizzo R., Caplan M., Cousin N., Duburcq T., Durand A., El kalioubie A., Favory R., Garcia B., Girardie P., Goutay J., Houard M., Jaillette E., Kostuj N., Ledoux G., Mathieu D., Moreau A.S., Niles C., Nseir S., Onimus T., Parmentier E., Préau S., Robriquet L., Rouze A., Six S., Verkindt H. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195–1199. doi: 10.1002/oby.22831. https://onlinelibrary.wiley.com/doi/abs/10.1002/oby.22831 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Chiumello D., Pozzi T., Storti E., Caccioppola A., Pontiroli A.E., Coppola S. Body Mass Index and ARDS severity in patients with and without SARS-CoV-2 infection. press on Brit J Anaesth. 2020 doi: 10.1016/j.bja.2020.07.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dixon A.E., Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12:755–767. doi: 10.1080/17476348.2018.1506331. [DOI] [PMC free article] [PubMed] [Google Scholar]